Skip to main content

Table 2 Multivariate CRC-specific survival analysis of different clinical stages in CRC patients with different sites

From: Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer

 

Cecum

Ascending colon HR (95% CI)

Transverse colon HR (95% CI)

Descending colon HR (95% CI)

Sigmoid colon HR (95% CI)

Rectum HR (95% CI)

Stage at presentation

 Stage 0

1.00

0.64 (0.48–0.85)*

1.18 (0.8–1.74)

1.25 (0.91–1.74)

0.98 (0.69–1.4)

1.14 (0.71–1.84)

 Stage I

1.00

0.58 (0.54–0.61)**

0.86 (0.79–0.93)**

1.07 (1–1.15)*

1.03 (0.95–1.1)

1.05 (0.96–1.16)

 Stage II

1.00

0.57 (0.54–0.6)**

0.78 (0.73–0.84)**

1 (0.95–1.06)

0.94 (0.89–0.99)*

0.91 (0.85–0.98)*

 Stage III

1.00

0.55 (0.52–0.58)**

0.81 (0.75–0.87)**

1.1 (1.03–1.18)*

0.98 (0.91–1.05)

0.87 (0.8–0.95)*

 Stage IV

1.00

0.58 (0.5–0.66)**

0.88 (0.75–1.04)

1.11 (0.96–1.28)

1.07 (0.92–1.24)

0.94 (0.78–1.13)

 All stages

1.00

0.56 (0.54–0.57)**

0.82 (0.78–0.85)**

1.07 (1.04–1.11)**

0.98 (0.95–1.02)

0.94 (0.89–0.98)*

  1. ** p < 0.001, *p < 0.05; CI confidence interval, HR hazard ratio. The classification criteria of stages refer to the AJCC/UICC TNM staging system. The cecum cancer group was set to 1 as the control group